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RPEde reductases A) are enzymes that reverse the effects of oxidative damage by
reducing methionine sulfoxide back to methionine and recovering protein function. In this study we
demonstrate that the transcriptional regulation of the human MSRA gene is complex and driven by two
distinct promoters. Both promoters demonstrate high expression in human brain and kidney tissues. The
upstream (promoter 1) regulates the msrA1 transcript that codes for the mitochondrial form of MSRA and is
highly active in a broad range of cell lines. The downstream promoter (promoter 2) regulates the msrA2/3
transcripts that code for the cytosolic/nuclear forms of MSRA and is generally less active. Promoter 2 contains
a 65 bp putative enhancer region that is very active in the retinal pigment epithelium-derived D407 cell line.
Both promoters are partially regulated by all-trans retinoic acid via RARA and other RARs.
Published by Elsevier Inc.IntroductionMethionine sulfoxide reductases (MSRs) are a family of anti-
oxidant enzymes that convert free or protein bound methionine
sulfoxide (MetO) back to methionine [1,2]. This process is known to
play a critical role in recovering protein functionality and in protection
against oxidative stress [3]. There are two distinct subfamilies of MSRs.
MSRAs are capable of reducing the S diastereomer, Met(S)O while
MSRBs reduce the R diastereomer, Met(R)O [4–7].
The importance of MSRAs in protection from oxidative stress and
in the aging process has been well documented [1,2]. MSRA over-
expression in yeast [8] and in human cell lines [9–12] increases their
resistance to oxidative stress and hypoxia. In rats, MSRA levels have
been shown to decrease with age [13]. MSRA knockout mice suffer
from neurological abnormalities, are more susceptible to oxidative
stress and have a 40% reduction in their lifespans [14]. In Drosophila,
MSRA overexpression increases lifespan and fertility as well as their
resistance to the insecticide paraquat [15]. In human WI-38
ﬁbroblasts, MSRA was found to be downregulated during replicative
senescence [9].
Our previous study demonstrated that the MSRA gene contained
two putative regulatory regions (promoters) 40 kbp apart which
generate three different transcripts [16]. These transcripts generateethionine sulfoxide reductase
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nc.different protein isoforms differing in their N-termini which in turn
determines their intracellular localizations [16]. The main transcript,
msrA1 (AY958429), is generated by promoter 1 and codes for themain
isoform of MSRA which localizes to the mitochondria [16,17]. The
other two transcripts, msrA2 (AY958430) and msrA3 (AY958431), are
generated by promoter 2 and code for two isoforms of MSRA that
localize to the cytosol and cytosol/nucleus, respectively [16]. The
msrA3 transcript was subsequently reported by another group which
also determined its nuclear/cytosolic localization [18]. More recently,
alternatively spliced forms of mitochondrial msrA have also been
identiﬁed in the rat [19].
In the retina, MSRA localizes to the retinal pigment epithelium
(RPE), photoreceptor synapses and ganglion cells [16] and may be
playing an important role in protecting these tissues from oxidative
and photo-damage [16,20]. In cultured RPE cells, siRNA-mediated
gene silencing increased their susceptibility to tertiary butyl-hydro-
peroxide [16] and hydrogen peroxide [20] induced cytotoxicity. In the
monkey retina, the macular RPE has very high levels of MSRA
expression [16]. This suggests that RPEmay be an appropriate tissue to
study MSRA transcriptional regulation.
The upstream human MSRA promoter (promoter 1) was partially
characterized recently [21], but little is known about the putative
downstream promoter (promoter 2) previously reported [16]. In this
study, we have determined that the putative promoter 2 is indeed
capable of initiating the transcription process that generates the
msrA2/3 transcripts (nuclear and cytosolic MSRA).We have found that
both promoters respond vigorously to all-trans retinoic acid (ATRA)
and that promoter 2 contains an enhancer region that may explain the
high MSRA expression observed in brain and RPE cells [16,20,22].
Table 1
List of oligonucleotide primers used for qRT-PCR and to generate promoter 1 and 2
deletion constructs
Primers for qRT-PCR (5′ to 3′)
18S F ATGCTCTTAGCTGAGTGTCCCG
R ATTCCTAGCTGCGGTATCCAGG
All msrAs F GCTTCGGCCCCATCACTAC
R GCCATTGGGGTTCTTGCTCA
msrA2–3 F GAGAGGCAGAGGGAGAGC
R TCAAGCCGAGAAAGCAGA
Primers to generate promoter constructs
Promoter 1
−1919 F AGTTTCACCCCGAAACCATCC
−1232 F CATGCCCAACTACCTTAAATACCTT
−408 F ACTGCCTTAATGGTGCTGTTGGTG
−24 to −1 R AACTTCGTCCCGAGAGAACCTCAG
Promoter 2
−1979 F AAGAGTACATTTATCCCATTTT
−1544 F GCTTCTCCAATGCTGCTTTCA
−971 F AGAACGTGGCAGAATCAAGGACTA
−499 F GACATTTCTGGGCATACGGTTTTA
−311 F CATATGGACATTTCTAGGGAACAGA
−208 F AGGATACCATGAAATCTGTAAGGTGA
−151 F GATTTGGGTACCGTACCACGGTT
−112 F TAATTGATCCGCAAAGGACATCT
−23 to −1 R TTGCCATACTGGGAGCAAAAGAGT
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Expression of msrA transcripts in different human tissues
In order to determine the tissue distribution of the different msrA
transcripts, qRT-PCR was performed on RNA from different human
tissues (Fig. 1). We were unable to design a primer set that could
unequivocally detect msrA1 so a primer set that detects all of the
msrAs was used and compared with a set that speciﬁcally detects
msrA2/3 (Table 1). Hence, Fig. 1A measures the contribution of both
promoters while Fig. 1B measures the contribution of promoter 2
speciﬁcally. All measurements were normalized to the 18S ribosomal
RNA and the neural retinawas given a value of 1. The values are shown
from highest to lowest (Fig. 1). Kidney (K), whole brain (B) and
cerebellum (C) were found to express the highest levels of all msrAs
(Fig.1A). However, in the case of transcripts derived from the promoter
2 (msrA2/3) whole brain and cerebellum showed considerably higher
expression than kidney (Fig. 1B). The neural retina (without the RPE
and choriocapillaris) had higher expression when compared to most
other tissues.
Activity of MSRA promoters in D407, HEK 293 and SH-SY5Y cell lines
To characterize and compare the MSRA upstream (promoter 1)
and downstream (promoter 2) promoters, three cell lines were
chosen which originated from tissues of known high MSRAFig. 1. Expression of msrA transcripts in different human tissues by qRT-PCR. (A)
Expression of all msrA transcripts (from promoters 1 and 2, Table 1). (B) Expression of
msrA2/3 transcripts (from promoter 2). The results are normalized with the 18S
ribosomal RNA. Data are presented as the mean of two independent experiments and
the error bars are the standard deviation of the individual measurements. A value of 1
was given to the retina. B, Brain; C, Cerebellum; H, Heart; K, Kidney; Li, liver; Lu, Lung;
Pl, placenta; Pr, prostate; R, Neural retina; SI, Small Intestine; SM, Skeletal Muscle; Sp,
Spleen; St, Stomach; T, Testis. The tissues were aligned from high to low and retina is
marked with a star.expression. The cell lines were D407 (RPE origin), HEK 293 (human
embryonic kidney cells) and SH-SY5Y cells (neuronal origin). Primers
were designed to amplify different areas of both promoters and the
fragments cloned into pGL4 luciferase reporter vector (Table 1). The
constructs were transfected into the different cell lines and luciferase
activity was measured (Fig. 2). The sequences for promoter 1 and 2
were submitted to GenBank and the accession numbers are as
follows: EU409840 for promoter 1 (−1919 to −1 bp) and EU409841
for promoter 2 (−1979 to −1 bp). The complete structure for the
human MSRA gene was previously published (16) but we have
included a brief diagram encompassing the promoter region (Fig. 2).
Please refer to reference 16 and the above GenBank ﬁles for more
speciﬁc information.
Constructs 1–2 (promoter 1, −1232 to −1, Fig. 3D) and 2–3
(promoter 2, −971 to −1, Fig. 3D) demonstrated the highest activity
(Fig. 3A) in D407 cells. In HEK 293 cells, promoter 1 was
approximately 10-fold more active than promoter 2 (Fig. 3B). The
construct 2–3 demonstrated a 2.7 fold increase in activity over the
control vector (pGL4). The construct 1–1 demonstrated slightly
greater activity than 1–2 in HEK 293 cells (Fig. 3B). These results
suggest the possibility that an upstream suppressor element is
present in the 1–1 construct which is active in D407 cells but not in
HEK 293 cells. In SH-SY5Y cells the activity for both promoters was
overall lower than in D407 and HEK 293 cell lines (Fig. 3C). In these
cells, promoter 1 activity was higher than promoter 2 (2–3 fold) but
contrasted sharply with the approximately 10-fold higher activity
observed in HEK 293 cells. SH-SY5Y cells demonstrated similar
activity for the different promoter 1 constructs (1–1, 1–2 and 1–3).
By contrast, the promoter 2 constructs behaved similarly in all the
cell lines tested, with construct 2–3 having the highest activity.
Overall, the data suggest that MSRA promoters may be regulated
differently depending on the tissue or organ.
Identiﬁcation of a putative enhancer in the 5′-distal region in promoter 2
In D407 cells, the considerable decrease in the promoter 2
activity observed between the constructs 2–3 and 2–4 (Fig. 3A)
suggested a potential enhancer in the region between −971 and
−499 (Fig. 3D). To localize the region responsible for this transcrip-
tional increase, four constructs of approximately 130–150 bp each
Fig. 2. Schematic map of MSRA gene promoters 1 and 2. The mitochondrial transcript msrA1 is formed by splicing exon 1–1 to exon 3. The cytosolic msrA2 splices exon 2–1 to exon 2
to exon 3. The nuclear/cytosolic msrA3 splices exon 2–1 to exon 3. After exon 3 all transcripts are identical. Formore details on the structure of theMSRA gene please refer to reference
16 and GenBank ﬁles EU409840 (promoter 1) and EU409841 (promoter 2).
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bars, Table 2). Only one of the constructs, between the positions
−731 to −598, demonstrated high luciferase activity similar to the
activity of the original 2–3 construct (Fig. 4). The 133 bp region
was further subdivided into three additional overlapping constructs
of approximately 65 bp each (Fig. 4, Table 3). The ﬁrst 65 bp (−731
to −666) did not have any activity, the middle region construct
(−693 to −628) demonstrated approximately 50-fold increase over
control and the last construct (−666 to −600) showed only a 10-fold
increase in activity (Fig. 4). These results suggest that the 65 bp region
between −693 and −628 is critical to the high expression observed in
D407 cells.Fig. 3. Activity of both MSRA promoters in D407, HEK 293 and SH-SY5Y and cell lines. Various
luciferase reporter vector and transfected into different cell lines. (A) Relative luciferase activity
SH-SY5Y neuroblastoma cell line. (D) Constructs used (Table 1). The activity of promoter 1 is r
Renilla luciferase transfection control and related to the pGL4 empty vector. Data (mean±SD oCharacterization of the promoter 2 putative enhancer region (−693 to
−628)
To further characterize this 65 bp enhancer region and to identify
speciﬁc response elements responsible for its high activity, ﬁve
different deletion constructs were made and analyzed (Fig. 5, Table 4).
Computer-aided analyses (www.gene-regulation.com/pub/databases.
html) suggested that the sequences TACTTGCT (deletion 1, putative
Oct-1 and/or Myf-3 element), GTTATTAAA (deletion 2, putative HNF-
1), AGATGTTTTA (deletion 3, putative HNF-3), TTTTCCTTTT (deletion 4,
putative GATA-1, Oct-1, ICSBP or RARA), and TATTTGTTTTA (deletion 5,
putative Oct-1, C/EBPα or HNF-3) may be areas of interest. All of theconstructs containing different areas of both MSRA promoters (D) were cloned into pGL4
of both promoters in D407 RPE-derived cell line. (B) HEK 293 kidney-derived cell line. (C)
epresented in dark grey and promoter 2 in light grey. All the results were normalized by
f three measurements) are representative of three or more independent experiments.
Fig. 4. Identiﬁcation of an enhancer region in promoter 2. The promoter 2 region between −971 and −475was subcloned into 4 regions: −971 to −828, −853 to −707, −731 to −598 and
−622 to −475 and the luciferase activity measured in transfected D407 cells (Table 2). The high activity region between −731 and −598 was further subcloned into three smaller
constructs: −731 to −666, −693 to −628 and −666 to −600 (Table 3). The empty vector (pGL4) and the 2–3 and 2–4 promoter 2 constructs were used for comparison. Data (mean±SD
of three measurements) are representative of three or more independent experiments.
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control. Constructs with deletions 1, 2 and 4 demonstrated diminished
activity while constructs with deletions 3 and 5 showed greatly
increased activity when compared to the original (−693 to −628).
Interestingly, deletions 3 and 5 contain a TGTTTTA sequence that may
be a suppressor element.
Effect of all-trans retinoic acid (ATRA) on the MSRA promoters
The computer-aided analysis of both promoter regions suggested
putative retinoic acid response elements (RARA) in both MSRA
promoters. Moreover, analysis of the 65 bp promoter 2 enhancer
region and the results from the above deletion constructs (deletion 4,
Fig. 5) which interfered with a putative RARA site suggested that these
element may be of importance.
To test this assumption D407 cells were transiently transfected
with constructs 1–2 and 2–3 and treated with increasing concentra-
tions of ATRA (0–15 μM), 18 h after transfection. The cells were
harvested 24 h after ATRA treatment and luciferase activity was
measured (Fig. 6A). Since ATRA may be toxic, cellular dehydrogenase
activity, a measure of cell viability, was monitored over the same
concentration range (Fig. 6B). The lower concentrations of ATRA (1
and 5 μM) roughly doubled the activity of both MSRA promoters (Fig.
6A) with no effect on cell viability (Fig. 6B). The promoter induction
was still measurable at 10 μM but cell viability was reduced by
approximately 25% (Figs. 6A and B). At 15 μM the loss in cell viability
was approximately 40% and this correlates with the drop in activity
observed for both promoters.
Expression of RARs in D407 cells
Since both MSRA promoters responded to ATRA we performed
immunoblots using speciﬁc antibodies to RARA, RARB and RARG toTable 2
List of oligonucleotide primers used to generate the 4 constructs to identify the
promoter 2 enhancer region
−971 to −828 F AGAACGTGGCAGAATCAAGGACTA
R TCTGTGCTTCACACACTTACCTGGT
−853 to −707 F ACCAGGTAAGTGTGTGAAGCACAGA
R CCTCAAGTTCCAGCATAGTCACT
−731 to −598 F AGTGACTATGCTGGAACTTGAGG
R CAGATGTACAGGGGAGAAGAGTTC
−622 to −475 F GAACTCTTCTCCCCTGTACATCTG
R TAAAACCGTATGCCCAGAAATGTCdetermine if they were expressed in nuclear extracts from D407 cells
(Fig. 7). The immunoblots indicate that all three RARs are expressed in
D407 cells (Fig. 7). For subsequent experiments we focused on RARA
for two particular reasons: RARA seems to be more abundant than the
other RARs and the computer-aided analyses indicated RARA-speciﬁc
elements.
Effect of RARA on the activity of MSRA promoters
To elucidate the effect of retinoic acid receptors on the activity of
theMSRApromoters, RARAwas overexpressed inD407 cells. One set of
D407 cells was co-transfected with the construct 1–2 (promoter 1,
−1232 to −1, Fig. 3D) and another set of cells with the construct 2–3
(promoter 2, −971 to −1, Fig. 2D). In addition, both set of cells received
the RARA construct and a control plasmid as a mock transfection
control. The cells were treated with 1 μM ATRA 18 h after transfection
and the luciferase activity was measured 24 h after the treatment. The
results from the experiments are shown in Fig. 8.
Without ATRA treatment, neither promoter responded to the RARA
overexpression (Figs. 8A and B, no treatment). As shown above (Fig. 6)
treatment with 1 μM ATRA increased the activity of both promoters
(Fig. 8). This effect was likely due to the constitutive expression of
RARs in D407 cells (Fig. 7). The cells co-transfected with the RARA
overexpression plasmid demonstrated an increase in activity for both
promoters (Figs. 8A and B) with promoter 2 being slightly more
responsive.
To conﬁrm the interaction of RARA with the MSRA promoters,
D407 cells were co-transfected with the luciferase construct 1–2 or 2–
3, and RARA siRNA or a negative control siRNA. The RARA siRNA used
suppressed the native RARA mRNA levels by 70% (data not shown).
The RARA siRNA attenuated the response of both promoters to ATRA
when compared to the siRNA negative control (Fig. 9). The reduction
was approximately 20%without ATRA treatment and around 40% after
the ATRA treatments.
The data suggest that RARA mediates the responses of both
promoters and promoter 2 may be somewhat more responsive to
ATRA than promoter 1.
Induction of native msrA transcripts by ATRA
To demonstrate that the transcriptional induction observed with
the luciferase reporter constructs was indeed relevant to MSRA
expression, msrA transcripts were measured by qRT-PCR in RNA from
D407 cells treated with ATRA (Fig. 10). The cells were treated with 0–
Table 3
List of oligonucleotides used to clone and narrow the promoter 2 enhancer region
Oligonucleotides for promoter 2 enhancer constructs
−731 to −666 F CTAGTGACTATGCTGGAACTTGAGGTGTCAAAATATGAAAAGATACTTGCTGTTATTAAATTGACCT
R AGCTAGGTCAATTTAATAACAGCAAGTATCTTTTCATATTTTGACACCTCAAGTTCCAGCATAGTCA
−693 to −628 F CTAGATACTTGCTGTTATTAAATTGACCTTAGATGTTTTATTTTCCTTTTTATTGTTATTTGTTTTA
R AGCTTAAAACAAATAACAATAAAAAGGAAAATAAAACATCTAAGGTCAATTTAATAACAGCAAGTAT
−666 to −600 F CTAGATGTTTTATTTTCCTTTTTATTGTTATTTGTTTTATCAAAAGAACTCTTCTCCCCTGTACATC
R AGCTCAGATGTACAGGGGAGAAGAGTTCTTTTGATAAAACAAATAACAATAAAAAGGAAAATAAAAC
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using the same primers and conditions as in Fig. 1 (Table 1). One
primer set measured all msrAs (Figs. 10A and B) and the other set
measured msrA2/3 from promoter 2 (Figs. 10C and D). Cell viability
was determined for both experiments (Figs. 10E and F) by assaying for
cellular dehydrogenase activity.
After 24 h all msrAs (msrA 1, 2 and 3) transcripts demonstrated a
dose-dependent induction (1.7 to 4-fold) over control at the 5 to 15 μM
concentrations (Fig. 10A). The msrA2/3 transcripts from promoter 2
seemed to bemore responsive with a 2.5–8 fold increase over controls
(Fig. 10C). After 48 h all msrAs increased by approximately 30 fold (Fig.
10B) at 15 μM. The msrA2/3 transcripts increased by approximately 18
fold (Fig. 10D) with 15 μM ATRA. The cell viability (cellular
dehydrogenase activity) was reduced by 20–30% with the 10 and
15 μM ATRA concentrations (Figs. 10E and F).
Discussion
In this study we demonstrate that the MSRA gene is regulated by
two distinct promoters. We partially characterized both MSRA
promoters with emphasis on the downstream, promoter 2. This
second MSRA promoter is particularly interesting because it regulates
the transcription of two distinct mRNAs that generate MSRA isoforms
with distinct N-termini that targets them to the cytosol and the
nucleus [16]. These isoforms have been previously described as
originating by alternative splicings [18,19] but we clearly demonstrate
that their expression is controlled by a second MSRA promoter. We
have also established that retinoic acid is involved in the regulation of
MSRA expression via RARA and suspect that other RAR isoforms may
also be involved.Fig. 5. Characterization of promoter 2 enhancer region. (A) Sequence of putative enhancer regi
(Table 4). All the results were normalized to the Renilla luciferase internal control and relateThe transcriptional regulation of MSRA is not well understood. In
Saccharomyces cerevisiae calcium phospholipid-binding protein
(CPBP), a homologue of elongation factor 1 gamma, has been shown
to regulate MSRA gene expression [24]. Also, in yeast, thioredoxins
have been shown to be essential for MSRA transcriptional activity [25].
In Drosophila the hormone ecdysone (essential in insect molting)
induced MSRA via the EcR-USP (ecdysone receptor-ultraspiracle)
complex [26]. EcR and USP belong to the same family of the
mammalian retinoic acids, thyroid hormone and vitamin D receptors
[27]. Thus, this previous work indirectly supports our ﬁndings
regarding the interactions of the MSRA promoters with retinoic acid
receptors.
In the human tissues analyzed by real time RT-PCR, brain and
kidney have much higher levels of msrAs than other tissues (Fig. 1A).
This higher expression in kidney and brain was previously described
by RNA dot blot analysis [28]. Kidney seems to be favored by promoter
1 which generates the mitochondrial msrA1 transcript [16,17].
Promoter 2 which controls the expression of the cytosolic and nuclear
transcripts msrA2/3 is most highly active in brain followed by the
kidney and neural retina (Fig. 1B). In the retina, MSRA is known to be
highly expressed in only three cell types, RPE, ganglion cells and
photoreceptors [16]. Using the same primer sets as in Fig. 1 and
monkey RNA from the RPE and choriocapillaris regions of the retina,
all msrAs (msrA1, 2 and 3) are expressed 4.5 fold more than in the
neural retina (data not shown). The msrA2/3 transcripts from
promoter 2 were 13 fold greater than in the monkey neural retina
(data not shown). Moreover, the RPE-derived D407 cells demon-
strated the highest level of activity for promoter 2 of all the cell lines
tested (Fig. 3). This suggests that MSRA may play an important role in
protecting the RPE from oxidative as well as retinoic acid damage.onmarking the deleted regions 1 thru 5. (B) Luciferase activity of the 5 deletion constructs
d to pGL4 empty vector. Data are expressed as mean±SD of three measurements.
Table 4
List of oligonucleotides used to delete different putative elements within the promoter
2 enhancer
Oligonucleotides with deletions
Del
1
F CTAGAGTTATTAAATTGACCTTAGATGTTTTATTTTCCTTTTTATTGTTATTTGTTTTA
R AGCTTAAAACAAATAACAATAAAAAGGAAAATAAAACATCTAAGGTCAATTTAATAACT
Del
2
F CTAGATACTTGCTTTGACCTTAGATGTTTTATTTTCCTTTTTATTGTTATTTGTTTTA
R AGCTTAAAACAAATAACAATAAAAAGGAAAATAAAACATCTAAGGTCAAAGCAAGTAT
Del
3
F CTAGATACTTGCTGTTATTAAATTGACCTTTTTTCCTTTTTATTGTTATTTGTTTTA
R AGCTTAAAACAAATAACAATAAAAAGGAAAAAAGGTCAATTTAATAACAGCAAGTAT
Del
4
F CTAGATACTTGCTGTTATTAAATTGACCTTAGATGTTTTAATTGTTATTTGTTTTA
R AGCTTAAAACAAATAACAATTAAAACATCTAAGGTCAATTTAATAACAGCAAGTAT
Del
5
F CTAGATACTTGCTGTTATTAAATTGACCTTAGATGTTTTATTTTCCTTTTTATTGT
R AGCTACAATAAAAAGGAAAATAAAACATCTAAGGTCAATTTAATAACAGCAAGTAT
Fig. 7. Expression of retinoic acid receptors in D407 nuclear extracts. RARA, RARB and
RARGwere detected by immunoblot using antibodies speciﬁc to each subtype. Each lane
contains 15 μg of nuclear protein extract. For more details see Materials and methods.
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evidence of tissue-speciﬁc suppressors (Fig. 3). In D407 cells there is a
doubling in promoter 1 activity between constructs 1–1 and 1–2 (Fig.
3A). This suggests the presence of a suppressor(s) between −1232
and −1919which affects D407 cells but not HEK 293 and SH-SY5Y (Fig.
3). In HEK 293 cells therewas a sharp decrease in activity between 1–2
and 1–3 (−1232 to −408). De Luca et al. [21] also in HEK 293 cells
demonstrated little change in activity between −1341 and −309 and a
large increase in activity between −309 and −155. Since De Luca et al.
[21] did not test any constructs between −1341 and −309 and we did
not test any promoter 1 constructs shorter than −408, it is difﬁcult to
make any direct comparison with our present results.
Promoter 2 also seems to have some suppressor activity between
−971 and −1979. This seems to be a general effect since it is similar inFig. 6. Effect of all-trans retinoic acid (ATRA) in the activity of MSRA promoters. D407
cells were transfected with constructs of promoter 1 (construct 1–2, −1232 to −1) and
promoter 2 (construct 2–3, −971 to −1). The cells were treated with ATRA 18 h after
transfection and luciferase activity was measure 24 h after ATRA treatment. (A) Relative
luciferase activity of promoter 1 and 2 constructs after treatment with ATRA. (B) Cell
viability (cellular dehydrogenase activity) of the cells at the different ATRA concentra-
tions. Data (mean±SD of three measurements) are expressed as the fold of luciferase
activity related to the activity of non-treated cells.all cell types (Fig. 3). Promoter 2 has only 2 to 3-fold increased activity
over control in HEK 293 and SH-SY5Y cells. However, construct 2–3
has approximately 25-fold increased activity over control in D407
cells. The reason(s) for this difference are unclear but cell-speciﬁc
interactions with the enhancer between −693 and −628 (Fig. 3) may
provide a partial explanation.
The 65 bp enhancer region identiﬁed in promoter 2 seems to
interact with multiple transcription factors. Deletion constructs in the
region between constructs 2–3 and 2–4 (Fig. 3) identiﬁed an area of
approximately 65 bp between −693 and −628 that provided highFig. 8. Effect of RARA overexpression on the activity of the MSRA promoters. RARA
expression construct was co-transfected with promoter 1 and promoter 2 luciferase
reporter constructs (1–2 and 2–3, respectively) in D407 cells. The cells were treated
with 1 μM ATRA 18 h after transfection and analyzed 24 h after ATRA treatment. (A)
Promoter 1 response. (B) Promoter 2 response. For more details see Materials and
methods. Data (mean±SD of three measurements) are representative of three
independent experiments.
Fig. 9. Effect RARA siRNA knockdown on the activity of MSRA promoters. D407 cells
were co-transfected with promoter 1 and promoter 2 luciferase reporter constructs (1–
2 and 2–3, respectively) and a siRNA for RARA or a negative siRNA control. The RARA
siRNA knocks down approximately 70% of the native RARA mRNA levels. After the co-
transfection (24 h), the cells were treated with 0.5, 1 and 5 μM ATRA and luciferase
activity was measured 24 h after the ATRA treatment. (A) Promoter 1 response. (B)
Promoter 2 response.
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deletions within the 65 bp enhancer region failed to completely
obliterate the activity (Fig. 4) and in two instances (deletions 3 and 5)
it was further increased. This region also has putative RARE elements
[29] and the deletion that disrupted these elements (Fig. 5) decreased
but did not eliminate the activity. This suggests that this putative
enhancer region is very important to the function of promoter 2.
ATRA, the natural agonist of RARs [29] has an important effect on
the transcriptional regulation of MSRA. D407 cells transfected with
promoter 1 and promoter 2 constructs (1–2 and 2–3, respectively)
and then treated with ATRA demonstrated a marked increase in
activity over controls (Fig. 6). RARs generally form heterodimers with
RXRs in the presence of their ligands then activate the RAREs in the
promoters of target genes [29–31]. In D407 cells, RARs and RXR are
expressed constitutively (Fig. 7). This effect of ATRA on the MSRA
promoter activity is mediated, at least in part, by RARA. Co-
transfection with plasmids overexpressing RARA in ATRA-treated
cells produced a measurable increase in the activity for both
promoters (Fig. 8). Promoter 2 responds more vigorously than
promoter 1 (Fig. 8) perhaps due to the putative RARE elements in the
65 bp enhancer region although this was not conclusively demon-
strated. The siRNA knockdown of RARA mRNA expression signiﬁ-
cantly attenuated the activity of both promoters and their response
to ATRA (Fig. 9).ATRA also had an effect on the native MSRA promoters in a dose-
dependent manner (Fig. 10). The response for promoter 2 was
detectable at 1–5 μM in 24 h and before any signiﬁcant cytotoxicity
was detected (Figs. 10C and E). The increased responses at the 1 and
5 μM ATRA concentrations (2–3 fold) were similar to those observed
with the shortened promoter constructs in Fig. 5A (please note scale
difference). However, both promoters responded vigorously at 15 μM
ATRA (Figs. 10B and D) after 48 h. At this concentration cytotoxicity
was signiﬁcant with approximately 30% cell death (Figs. 10E and F).
Thus, the 18 and 30-fold increases in activity observed with 15 μM
ATRA in 48 h (Fig. 10, promoter 2 and all promoters, respectively) may
also be attributed to cell stress and not exclusively to ATRA. This stress
response by both promoters needs to be further investigated.
The ﬁndings of retinoic acids involvement in the transcriptional
regulation of MSRAs are not only novel but potentially very important.
Retinoic acids have been shown to modulate anti-oxidant enzymes in
different tissues [32,33]. In the retina, ATRA is generated by the
photoreceptors and RPE as a by-product of the visual process [34].
Retinoic acids can induce apoptosis in RPE cells [32] by generating
reactive oxygen species [32,35]. The generation of reactive oxygen
species seems to be due to a direct effect of retinoic acids on the
mitochondria [36,37]. Thus, our data suggests that MSRA may be part
of a pro-active protective mechanism that responds to ATRA before
reactive oxygen species are formed. This may be of particular
importance to the retina and RPE cells in particular because of the
relative large amounts of ATRA generated in this tissue [34].
Our ﬁndings, when taking in context with what is known about
MSRA's function, suggest that this enzyme plays an important role in
the anti-oxidative mechanisms of the RPE and possibly in the
pathogenesis of RPE-related diseases like age-related macular degen-
eration [38]. This disease as well as others may beneﬁt from increased
expression of MSRA. Thus, understanding the transcriptional regula-
tion of this gene may provide some potential pharmacological
solutions to prevent neuronal damage especially in aging diseases.
Materials and methods
Materials
Human total RNAs were purchased from BD Biosciences (Mountain
View, CA). Human genomic DNA was purchased from Clontech
(Mountain View, CA). Oligonucleotides were purchased from Inte-
grated DNA Technologies, Inc. (Coralville, IO). Endonucleases were
purchased from New England Biolabs (Ipswich, MA). ATRA was
purchased from Sigma (St. Louis, MS) and used dissolved in DMSO.
The transfection control plasmid pRL-TK (thymidine kinase promoter
of Herpes Simplex virus with Renilla luciferase reporter gene) was
purchased from Promega (Madison, WI). Mouse anti-human RARA
andmouse anti-human RARB antibodies were purchased from Biomol
International Inc. (Plymouth Meeting, PA). Rabbit anti-human RARG
was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
RNA isolation and reverse transcription
Total RNA from D407 cells was isolated with Qiagen RNeasy mini
kit using a QiaCube instrument (Qiagen, Valencia, Ca) following the
manufacturer's protocol. cDNAwas synthesized from 2 μg of total RNA
previously treated with DNase I (Invitrogen Corp, Carlsbad, CA) in a
20 μL reaction using SuperScript III Reverse Transcriptase (Invitrogen
Corp, Carlsbad, CA).
Real time semi-quantitative RT-PCR
Real time semi-quantitative RT-PCR (qRT-PCR) was performed
using SYBR green in an ABI 7500 instrument (Applied Biosystems Inc.,
Foster City, CA). A serial dilution of cDNA from the same source as
Fig. 10. Effect of ATRA on the expression of native msrA transcripts. D407 cells were treated with 0, 1, 5, 10 and 15 μM of ATRA for 24 h and 48 h. Expression of msrA transcripts was
determined by qRT-PCR using the same primers and conditions as Fig.1 (Table 1). (A) All msrA transcripts (msrA1, 2 and 3) from both promoters. (B) MsrA transcripts from promoter 2
(msrA2/3). Cell viability (cellular dehydrogenase) was performed under the same treatment conditions. (C) Cell viability 24 h after treatment. (D) Cell viability 48 h after treatment.
Values were normalized to the 18S ribosomal RNA and related to the control. Data are presented like mean±SD of at least three samples.
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quantiﬁed by determining the cycle threshold (Ct) and using the
calibration curves. The relative values were normalized with 18S
ribosomal RNA. Primers to quantify all msrAs were designed between
exons 5 and 6 and primers for msrA2/3 transcripts were designed on
exon 2–1 (Table 1, and reference 16).
Preparation of luciferase reporter constructs
Different areas of promoters 1 and 2 were ampliﬁed from human
genomic DNA beginning at the transcription start site to different 5′
upstream region. The transcription start sites for all three transcripts
were previously determined by 5′RACE [16]. The ampliﬁcations were
performed using pfu DNA polymerase (Stratagene, La Jolla, CA). The
PCR products were puriﬁed using the PCR puriﬁcation Kit from
Qiagen (Valencia, CA). The puriﬁed products were mixed with
pGL4.10 reporter vector (Promega Corp, Madison, WI) which had
been previously digested with EcoRV endonuclease and ligated using
the Quick Ligase Kit (New England Biolabs, Ipswich, MA). Primersused to amplify promoters 1 and 2 are listed in the Table 1. Promoter
sequences around 65 bp or less were cloned using adapter oligos
with NheI and HindIII ends into pGL4.10 vector digested with the
same endonucleases. All constructs were veriﬁed by direct
sequencing.
Cloning of human RAR for expression
The open reading frame of RARA transcription factor was ampliﬁed
by PCR from human retina cDNA using the forward primer, 5′-
ACCATGGCCAGCAACAGCAG-3′ and the reverse primer, 5′-ATT-
CACGGGGAGTGGGTGG-3′. PCR products were cloned into pcDNA
3.1/V5-His-TOPO vector (Invitrogen Corp, Carlsbad, CA) which drives
expression using the CMV promoter.
DNA sequencing
Sequencing of the different plasmid constructs was performed
using the BigDye terminator v3.1 cycle sequencing kit and an ABI 3130
70 I. Pascual et al. / Genomics 93 (2009) 62–71Genetic Analyzer instrument (Applied Biosystems Inc., Foster City, CA)
following the manufacturer's protocol.
Cell cultures
HEK 293 and SH-SY5Y cells were purchased from American Type
Culture Collection (Manassas, VA). D407 cells were a kind gift from Dr.
Richard Hunt (Department of Pharmacology and Microbiology,
University of South Carolina, Columbia, SC). D407 were grown in
DMEM medium supplemented with 4% fetal bovine serum (FBS).
HEK293were grownwith DMEM supplementedwith 10% FBS and SH-
SY5Y neuroblastoma cells were grown with DMEM/F12 (1:1)
supplemented with 10% FBS. Penicillin 10 U/mL, streptomycin
100 μg/μL and 2 mM of L-glutamine were added to all the cell
media. DMEM and DMEM/F12 media were purchased from Atlanta
biologicals (Atlanta, GA) and all other components used for cell culture
were from Invitrogen Corp (Carlsbad, CA).
Transient transfections and expression
The transfections were performed on 1×106 cells by electropora-
tion using the Cell Line nucleofector V Kit and the Nucleofector™ II
instrument (Amaxa Biosystems Inc., Gaithersburg, MD) according to
the manufacturer's protocol. D407, SH-SY5Y and HEK293 cells were
co-transfected with the different hMSRA-pGL4 constructs and a Re-
nilla luciferase transfection control plasmid pRL-TK. Cells were plated
on 24-well plates and fresh media was added 18 h after transfection.
To determine the effects of RARA overexpression on the activity of
MSRA promoters, D407 cells were transfected with 0.5 μg of the
MSRA-pGL4 constructs, 1–2 or 2–3, 10 ng pRL-TK, and 4 μg of the
expression plasmid RARA. The plasmid vector pcDNA 3.1/V5-His-
TOPO/lacZ (Invitrogen Corp, Carlsbad, CA) was used for the mock
transfections.
Knockdown of RARA using small interference RNA (siRNA)
The RARA siRNA (cat# SI00019369) and a negative control siRNA
(cat# 1022083) were purchased from Qiagen Inc. (Valencia, CA). D407
cells (2×106 cells) were transfected with 500 nM of each siRNA as
described above. The silencing of RARA siRNA was monitored by real
time PCR using the forward primer, 5′-TGCCCAGCTCACCACATCTTCAT-
3′ and the reverse primer, 5′-CTGTCCCACCCCCTCTGTCACCAA-3′.
Cell viability assay
Cell viability was measured using the Cell Counting Kit-8
purchased from Dojindo Molecular Technologies, Inc. (Gaithersburg,
MD). This assay measures cellular dehydrogenase activity. Absorbance
was measured in a Wallac 1420 Victor 2 instrument (Perkin Elmer Inc,
Waltham, MA).
Luciferase reporter assay
Luciferase expression was measured using the Dual-Luciferase
Reporter Assay System (Promega) in a POLARstar OPTIMA Multi-
function Microplate Reader instrument (BMG LABTECH Inc., Durham
NC). The luciferase activity was quantiﬁed 48 h after transfection and
normalized to the Renilla luciferase internal transfection control.
Treatment with all-trans retinoic acid
All experiments where ATRA was used were performed in dim
yellow light to avoid photooxidation. In the studies where the effects
of ATRA on MSRA promoter activity was measured (Figs. 6 and 8),
ATRA (1, 5, 10 and 15 μM, ﬁnal concentration) was added to the cells
18 h after transfection and the cells were harvested 24 h after ATRAtreatment. In the studies where ATRAwas used to induce msrA mRNA
expression, 3×105 cells were seeded and the cells treated (in 6-well
plates) for 24 and 48 h.
Immunoblots
Nuclear extracts were prepared from D407 cells as previously
described [23]. Nuclear proteins (15 μg per lane) were separated in 4–
12% SDS-polyacrylamide gels (NuPAGE, Invitrogen Corp. Carlsbad, CA).
Proteins were blotted on to nitrocellulose membranes using an iBlot
dry blotting system (Invitrogen Corp.) following the manufacturer's
protocol. The membranes were blocked with 5% non-fat milk (BioRad
Laboratories, Inc., Hercules, CA). The membranes were then incubated
overnight with primary antibodies speciﬁc to RARA, RARB and RARG
(see above). The blots were developed with anti-mouse (RARA and
RARB) or anti-rabbit (RARG) horseradish conjugated secondary
antibodies using Super Signal West Pico chemiluminescent substrate
(Pierce Biotechnology Rockford, IL).
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